A statement released earlier today by Bankhaus Lampe KG about EVOTEC (ETR:EVT) bumps the target price to 6.50EUR
- Updated: November 26, 2016
Boasting a price of 6.06EUR, EVOTEC (ETR:EVT) traded 0.50% higher on the day. With the last stock price close down -0.01% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. EVOTEC has recorded a 50-day average of 19.68EUR and a two hundred day average of 20.25EUR. Volume of trade was down over the average, with 72,804 shares of EVT changing hands under the typical 138,516
Bankhaus Lampe KG bumped up the target of EVOTEC (ETR:EVT) to 6.50EUR stating a potential upside of 0.07%.
On 11/26/2016, Bankhaus Lampe KG released a statement for EVOTEC (ETR:EVT) bumped up the target price from 0.00EUR to 6.50EUR that suggested an upside of 0.07%.
With a total market value of 0 EUR, EVOTEC has with a one year low of 16.37EUR and a one year high of 21.25EUR .
Brief Synopsis About EVOTEC (ETR:EVT)
Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for collaborator's targets and programs. EVT Innovate focuses on developing its internal assets, including early-stage discovery programs, as well as drug candidates. The Company focuses on therapeutic areas, including central nervous system (CNS)/neurology, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. Its clinical products include EVT302, EVT201, EVT100 and EVT401. Its pre-clinical products include EVT770, EVT801, EVT701 and EVT601. EVT302 is an inhibitor of monoamine oxidase type B (MAO-B), an enzyme that breaks down the chemical messenger dopamine in the brain and contributes to the production of free radicals.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.